**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Brett W. Sperry, MD. Saint Luke's Mid America Heart Institute, Kansas City, MO.

**Main Body of the Abstract**
Background: The rate of diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) has increased over the years, in part due to non-invasive diagnostic methods and treatment options that improve morbidity and mortality.
Methods: Individual patient level data at 5 cardiac amyloid centers (Cleveland Clinic, Columbia, Saint Luke’s Mid America Heart Institute, Oregon Health Sciences, and University of Pittsburgh) were used to evaluate the trends over time in all-cause mortality for patients diagnosed with ATTR-CM. Mortality was compared by era (pre 2010, 2010-2013, 2014-2017, and 2018-2021) and by NAC and Columbia stage using Kaplan-Meier curves.
Results: Among 1168 subjects, those with a more recent diagnosis of ATTR-CM were more likely to be older, white, have wild type disease, and have lower NYHA classes. All-cause mortality was lower in the more recent eras (p<0.0001). In patients with data available to calculate NAC stage (n=1027), disease severity was relatively stable over time (p=0.868), while Columbia stage (n=960) showed more patients with early stage disease in the more recent eras (p=0.006). All-cause mortality was lower in more recent eras only for NAC and Columbia Stage 1 patients (Figure).
Conclusions:  In this real-world multicenter study of patients with ATTR-CM, diagnosis in a more recent era is associated with improved all-cause mortality and is driven by patients diagnosed at an earlier stage of disease.



Reduction in All-Cause Mortality in ATTR-CM Over a 20 year Period PC74 (#453)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.